CX 2024 Preliminary Programme
Day 1: Peripheral Arterial Controversies - Tuesday, 23rd April
Venue: Theatre 1
Paclitaxel Mortality Controversy
Audience participation & discussion & polling
Update on the safety of paclitaxel-coated balloons for femoropopliteal occlusive disease
| Speaker: | Thomas Zeller, Bad Krozingen, Germany |
Paclitaxel and mortality
| Speaker: | Peter Schneider, San Francisco, United States |
Did the meta-analysis and regulatory body restrictions on paclitaxel cause harm
| Speaker: | TBA |
Final perspective from regulatory authorities
Audience participation & discussion & polling
Drug-Coated Balloons in the Femoropopliteal Arteries
Pacliaxel and Sirolimus Coated Ballloons in the Femoro-popliteal Arteries: Mechanisms of Action
| Speaker: | TBA |
Audience participation & discussion
Long-term success with a market leading Paclitaxel DCB: The IN.PACT RCT and Global Registry
| Speaker: | Gunnar Tepe, Rosenheim, Germany |
Audience participation & discussion
Three-year outcomes after paclitaxel-coated balloon angioplasty of femoropopliteal arteries among patients in the French National Health Data System
| Speaker: | Yann Goueffic, Paris, France |
Audience participation & discussion
Trials in the SFA: SFA IDE and SUCCESS PTA Trials
| Speaker: | Michael Lichtenberg, Arnsberg, Germany |
Audience participation & discussion
Asian trials including future SFA Asia RCT
| Speaker: | Edward Choke, Bukit Merah, Singapore |
Audience participation & discussion
Sirolimus vs Paclitaxel: A head to head trial: Update of the SIRONA RCT
| Speaker: | TBA |
Audience participation & discussion
Debate: After the FDA announcement paclitaxel-coated devices now beat Limus coated devices
For the motion
| Andrew Holden, Auckland, New Zealand |
Against the motion
| Marianne Brodmann, Graz, Austria |
Audience participation & discussion
Sponsored education
Bioresorbable Scaffolds in Tibial Arteries
Bioresorbable scaffolds in tibial arteries: The holy grail?
| Speaker: | Ramon Varcoe, Sydney, Australia |
Audience participation & discussion
Latest data release from the LIFE-BTK clinical trial
| Speaker: | Brian DeRubertis, Los Angeles, United States |
Audience participation & discussion
Update on stenting in the tibial arteries
| Speaker: | Michel Bosiers, Bern, Switzerland |
Audience participation & discussion
First-in-human experience with a bioresorbable scaffold in the femoropopliteal segment
| Speaker: | Andrew Holden, Auckland, New Zealand |
Audience participation & discussion
Vessel Preparation in Tibial Artery Occlusive Disease
What are the concepts behind vessel preparation devices?
Audience participation & discussion
What is the evidence for vessel preparation with atherectomy in BTK arteries?
| Speaker: | Thomas Zeller, Bad Krozingen, Germany |
Audience participation & discussion
An update on IVL in BTK arteries: Data and new technologies
| Speaker: | Andrew Holden, Auckland, New Zealand |
Audience participation & discussion
Choco-Cabana: A prospective, randomised trial comparing a novel PTA balloon versus conventional PTA for sustained lumen gain below-the-knee
| Speaker: | Gunnar Tepe, Rosenheim, Germany |
Audience participation & discussion
Are vessel preparation devices cost-effective
| Speaker: | TBA |
Audience participation & discussion: Atherectomy, Lithotripsy and other Vessel Preparation Devices - competitive or complimentary technologies?
Sponsored education
Inaugural Roger M Greenhalgh Late Breaking Trials Session
Roger M Greenhalgh: A Focus on Deep Venous Arterialisation
Transcatheter arterialisation of the deep veins: Highlights of the PROMISE trials
| Speaker: | Daniel Clair, Columbia, United States |
Audience participation & discussion
New data from the CLARITY Trial
| Speaker: | Anahita Dua, Boston, United States |
Audience participation & discussion
Late Breaker: Final results from the PROMISE UK trial
| Speaker: | Hany Zayed, London, United Kingdom |
Audience participation & discussion
The PiPeR DVA technique
| Speaker: | Bruno Migliara, Peschiera del Garda, Italy |
Audience participation & discussion
New considerations in DVA
| Speaker: | Steven Kum, Singapore, Singapore |
Audience participation & discussion
Post DVA management
| Speaker: | Uei Pua, Singapore, Singapore |
Audience participation & discussion
Deep Venous Arterialization: A word of caution
| Speaker: | Thomas Zeller, Bad Krozingen, Germany |
Audience participation & discussion
Aorto-iliac Occlusive Disease
A new classification for aorto-iliac occlusive disease
| Speaker: | TBA |
Audience participation & discussion
Updated results from the discover RCT
Audience participation & discussion
An update of the Forward clinical study
| Speaker: | Andrew Holden, Auckland, New Zealand |
Audience participation & discussion
Intravascular lithotripsy in AIOD
Audience participation & discussion
Latest data on covered endovascular repair of the aortic bifurcation
Audience participation & discussion
Sponsored education
BASIL-3 Podium First Presentation
| Anchor: | Andrew Holden, Auckland, New Zealand |
| Moderator: | Dittmar Boeckler, Heidelberg, Germany |
Opening remarks and introduction
| Speaker: | Andrew Bradbury, Birmingham, United Kingdom |
Background
Methodology
Putting BASIL-3 in context
Limitations
Interpretation and future work
| Speaker: | Andrew Bradbury, Birmingham, United Kingdom |
Audience participation & roundtable discussion
Great Debate: Is bypass surgery better than endovascular surgery?
For the motion
| Andrew Bradbury, Birmingham, United Kingdom | |
| Andrew Holden, Auckland, New Zealand |
Against the motion
| Matthew Menard, Boston, United States | |
| Michael Conte, San Francisco, United States |